References
- Wellcome Global Monitor 2018.( published 2019 June 19); [accessed 2019 July 2]. https://wellcome.ac.uk/reports/wellcome-global-monitor/2018
- Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, et al. Type diabetes trialnet study group. An Anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019. doi:10.1056/NEJMoa1902226.
- Drolet M, É B, Pérez N, Brisson M. HPV vaccination impact study group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019. doi:10.1016/S0140-6736(19)30298-3.
- Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019;25(6):941–46. doi:10.1038/s41591-019-0448-9.
- Beernink PT, Vianzon V, Lewis LA, Moe GR, Granoff DM. A meningococcal outer membrane vesicle vaccine with overexpressed mutant FHbp elicits higher protective antibody responses in infant rhesus macaques than a licensed serogroup B vaccine. MBio. 2019;10:3. doi:10.1128/mBio.00669-19.